Oncology

18F-fluorodeoxyglucose positron emission tomography with computed tomography (FDG-PET-CT) for oncological indications

9 October 2023

Published on 01 Oct 2018
Last Updated on 09 Oct 2023

Guidance Recommendations

The Ministry of Health’s Medical Technology Advisory Committee has recommended subsidy for 18F-fluorodeoxyglucose positron emission tomography with computed tomography (FDG-PET-CT)

➢ for the management of the following oncological indications:

Table caption

All subtypes of the following tumours:	Limited subtypes of the following tumours:
Cervical cancer Colorectal cancer Non-small-cell lung cancer Solitary pulmonary nodule Hodgkin’s disease (lymphoma) Non-Hodgkin’s disease (lymphoma) Melanoma Myeloma Oesophageal and oesophago-gastric junction cancer Ovarian cancer	Breast cancer Locally advanced (Stage III) disease Suspected recurrent disease Central nervous system cancer Suspected residual or recurrent malignant brain cancer Head and neck cancer Nasopharyngeal cancer Squamous cell carcinomas Salivary gland tumours Sarcoma High/intermediate grade sarcomas or clinically aggressive sarcomas Ewing’s sarcoma Osteosarcoma Rhabdomyosarcoma

➢ only the approved FDG-PET-CT functions as per Annex should be subsidised for the above indications.

Funding status

FDG-PET-CT is recommended for subsidy for the management of patients with selected oncological indications, in line with the abovementioned recommendations.

Subsidies will not apply to other oncological indications or PET-CT services utilising non-FDG tracers.

FDG-PET-CT for oncological indications [PDF, 244 KB] (opens in new tab)